Evidence map›Paper›PMID 39099560›Full record

ArticleClinical kidney journal2024

Further improvement of circuit survival in citrate based continuous renal replacement therapy.

Alena Post, Èmese R H Heijkoop, Lotte L M Diebels, Adrian Post, Matijs van Meurs, Peter H J van der Voort, Casper F M Franssen, Meint Volbeda

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical kidney journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Alena PostDepartment of Critical Care, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Èmese R H HeijkoopDepartment of Critical Care, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Lotte L M DiebelsDepartment of Critical Care, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Adrian PostDepartment of Nephrology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.ORCID https://orcid.org/0000-0001-8645-1627
Matijs van MeursDepartment of Critical Care, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Peter H J van der VoortDepartment of Critical Care, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Casper F M FranssenDepartment of Nephrology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Meint VolbedaDepartment of Critical Care, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.ORCID https://orcid.org/0000-0001-7641-1330

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Continuous renal replacement therapy (CRRT) is the most frequently used modality of renal replacement therapy (RRT) in critical care patients with acute kidney injury (AKI). Adequate CRRT delivery can be challenging, due to problems with circuit patency. To improve circuit patency, we developed a new CRRT protocol using continuous veno-venous hemodiafiltration (CVVHDF) with 3.0 mmol/l regional citrate anticoagulation (CVVHDF/RCA3.0) as our first choice RRT modality. Methods: Retrospective comparison of efficacy and safety of a CVVHDF/RCA3.0 protocol with our former continuous veno-venous hemofiltration protocol with 2.2 regional citrate anticoagulation (CVVH/RCA2.2) in adult critically ill patients with AKI requiring CRRT between 25 April 2020 and 24 October 2021. Results: In total, 56 patients (257 circuits) and 66 patients (290 circuits) were included in the CVVH/RCA2.2 and CVVHDF/RCA3.0 groups, respectively. Median circuit survival was significantly higher in patients treated with CVVHDF/RCA3.0 (39.6 (IQR 19.5-67.3) hours) compared to patients treated with CVVH/RCA2.2 (22.9 (IQR 11.3-48.6) hours) ( Conclusions: CRRT circuit survival was longer with CVVHDF/RCA3.0 compared to CVVH/RCA2.2. CRRT circuit survival was negatively associated with higher body weight and higher convective flow.

Indexed as

acute kidney injurycontinuous renal replacement therapycontinuous veno-venous hemodiafiltrationcontinuous veno-venous hemofiltrationregional citrate anticoagulation

Identifiers

PMID39099560
PMCPMC11292220

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.